[en] Nondepleting anti-CD25 monoclonal antibodies (daclizumab) and depleting polyclonal antithymocyte globulin (Thymoglobulin) both prevent acute rejection, but these therapies have not been directly compared in a high-risk, HLA-sensitized renal transplant population. We randomly assigned 227 patients, who were about to receive a kidney graft from a deceased donor, to either Thymoglobulin or daclizumab if they met one of the following risk factors: current panel reactive antibodies (PRA) >30%; peak PRA >50%; loss of a first kidney graft from rejection within 2 yr of transplantation; or two or three previous grafts. Maintenance immunosuppression comprised tacrolimus, mycophenolate mofetil, and steroids. Compared with the daclizumab group, patients treated with Thymoglobulin had a lower incidence of both biopsy-proven acute rejection (15.0% versus 27.2%; P = 0.016) and steroid-resistant rejection (2.7% versus 14.9%; P = 0.002) at one year. One-year graft and patient survival rates were similar between the two groups. In a comparison of rejectors and nonrejectors, overall graft survival was significantly higher in the rejection-free group (87.2% versus 75.0%; P = 0.037). In conclusion, among high-immunological-risk renal transplant recipients, Thymoglobulin is superior to daclizumab for the prevention of biopsy-proven acute rejection, but there is no significant benefit to one-year graft or patient survival.
Disciplines :
Surgery
Author, co-author :
Noel, Christian
Abramowicz, Daniel
Durand, Dominique
Mourad, Georges
Lang, Philippe
Kessler, Michele
Charpentier, Bernard
Touchard, Guy
Berthoux, Francois
Merville, Pierre
Ouali, Nacera
Squifflet, Jean-Paul ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Wissing KM, Fomegne G, Broeders N, Ghisdal L, Hoang AD, Mikhalski D, Donckier V, Vereerstraeten P, Abramowicz D: HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 85: 411-416, 2008 (Pubitemid 351322766)
Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS: Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 7: 1359-1375, 2007
Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC: Interleukin 2 receptor antagonists for renal transplant recipients: A metaanalysis of randomized trials. Transplantation 77: 166-176, 2004 (Pubitemid 38155741)
Vincenti F, de Andrés A, Becker T, Choukroun G, Cole E, Gonzalez- Posada JM, Kumar MA, Moore R, Nadalin S, Nashan B, Rostaing L, Saito K, Yoshimura N: Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int 19: 446-457, 2006 (Pubitemid 43736340)
Patlolla V, Zhong X, Reed GW, Mandelbrot DA: Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 7: 1832-1842, 2007 (Pubitemid 46905449)
Opelz G, Naujokat C, Daniel V, Terness P, Dohler B: Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 81: 1227-1233, 2006 (Pubitemid 43804539)
Zaltzman JS, Boucher A, Busque S, Halloran PF, Landsberg DN, McAlister VC, Russell D, Shoker A, Shapiro J, Tchervenkov JI, Ferguson R: A prospective 3-yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high risk renal allograft recipients. Clin Transplant 19: 26-32, 2005 (Pubitemid 40227848)
Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC: Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 6: 2384-2390, 2006 (Pubitemid 44359424)
Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S: A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6: 346-351, 2006 (Pubitemid 43382170)
Anglicheau D, Loupy A, Suberbielle C, Zuber J, Patey N, Noel LH, Cavalcanti R, Le Quintrec M, Audat F, Mejean A, Martinez F, Mamzer- Bruneel MF, Thervet E, Legendre C: Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study. Am J Transplant 7: 1185-1192, 2007 (Pubitemid 46643104)
US Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients. 2006 Annual Report: Transplant Data 1996-2005. http://www.optn.org/AR2006/. 2006 Ref Type: Electronic Citation
Agence de la Biomedecine. Assistance medicale a la procreation 2002-2003-2004. http://www.agence-biomedecine.fr/fr/rapport-2005/ som/som-assist-1.htm. 2005 Ref Type: Electronic Citation
Vitko S, Wlodarczyk Z, Kyllonen L, Czajkowski Z, Margreiter R, Backman L, Perner F, Rigotti P, Jaques B, Abramowicz D, Kessler M, Sanchez-Plumed J, Rostaing L, Rodger RS, Donati D, Vanrenterghem Y: Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 6: 531-538, 2006 (Pubitemid 43382139)
Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N: Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7: 1506-1514, 2007 (Pubitemid 46776239)
Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575, 2007 (Pubitemid 350294223)
Szczech LA, Berlin JA, Feldman HI: The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 128: 817-826, 1998
Brennan DC, Daller JA, Lake KD, Cibrik D, Del CD: Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355: 1967-1977, 2006 (Pubitemid 44708016)
Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, Bozorgzadeh A, Sanz I, Briggs BJ: Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79: 1507-1515, 2005 (Pubitemid 40847581)
Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC: Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359: 242-251, 2008 (Pubitemid 352008439)
Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II: The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 78: 190-193, 2004 (Pubitemid 39525336)
Gentry SE, Segev DL, Simmerling M, Montgomery RA: Expanding kidney paired donation through participation by compatible pairs. Am J Transplant 7: 2361-2370, 2007 (Pubitemid 47347858)
Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC: Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 331: 810, 2005 (Pubitemid 41442360)
Opelz G: Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 60: 1220-1224, 1995
Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Marcussen N, Mihatsch MJ, Nadasdy T, Nickerson P, Olsen TS, Papadimitriou JC, Randhawa PS, Rayner DC, Roberts I, Rose S, Rush D, Salinas-Madrigal L, Salomon DR, Sund S, Taskinen E, Trpkov K, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999 (Pubitemid 29082898)
